Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $262.2 million.

  • Integra Lifesciences Holdings' Receivables - Net rose 558.28% to $262.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.2 million, marking a year-over-year increase of 558.28%. This contributed to the annual value of $272.4 million for FY2024, which is 502.96% up from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Receivables - Net stood at $262.2 million for Q3 2025, which was up 558.28% from $284.5 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Receivables - Net's 5-year high stood at $284.5 million during Q2 2025, with a 5-year trough of $222.2 million in Q3 2021.
  • In the last 5 years, Integra Lifesciences Holdings' Receivables - Net had a median value of $252.4 million in 2025 and averaged $250.0 million.
  • Data for Integra Lifesciences Holdings' Receivables - Net shows a peak YoY increase of 2829.02% (in 2021) and a maximum YoY decrease of 896.13% (in 2021) over the last 5 years.
  • Integra Lifesciences Holdings' Receivables - Net (Quarter) stood at $231.8 million in 2021, then rose by 13.65% to $263.5 million in 2022, then fell by 1.57% to $259.3 million in 2023, then grew by 5.03% to $272.4 million in 2024, then fell by 3.75% to $262.2 million in 2025.
  • Its last three reported values are $262.2 million in Q3 2025, $284.5 million for Q2 2025, and $252.4 million during Q1 2025.